Recent Updates
Recently added Catalysts
KRYS Positive Sentiment Score: 75/100

Krystal Biotech to Present at BofA Securities 2025 Health Care Conference

Key Takeaway: Krystal Biotech, Inc. (NASDAQ: KRYS) will present at the BofA Securities 2025 Health Care Conference on May 14, 2025, in Las Vegas. The company's CEO, Krish S. Krishnan, is scheduled to participate in a fireside chat at 11:20 am PT and will hold investor meetings throughout the day. A webcast of the presentation will be made available on the company's website. Krystal Biotech is known for its genetic medicines targeting high unmet medical needs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Company is participating in a prominent health care conference.
  • Fireside chat indicates engagement with investors and stakeholders.
  • Krystal Biotech is advancing a robust pipeline of genetic medicines.

Full Press Release Details

PITTSBURGH, May 07, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2025 Health Care Conference on May 14, 2025, in Las Vegas. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 11:20 am PT and host investor meetings throughout the day.
A webcast of the presentation will be available here beginning at 11:20 am PT on Wednesday, May 14, 2025 and will be posted on the Investors section of the Company’s website.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy, and the first genetic medicine approved by the FDA and EMA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
Investors and Media:

Frequently Asked Questions

When is Krystal Biotech participating in the BofA Securities Conference?

Krystal Biotech will participate on May 14, 2025.

Who will represent Krystal Biotech at the conference?

Krish S. Krishnan, CEO, will represent the company.

What is VYJUVEK® by Krystal Biotech?

VYJUVEK® is the first-ever redosable gene therapy approved for dystrophic epidermolysis bullosa.

Where is Krystal Biotech headquartered?

Krystal Biotech is headquartered in Pittsburgh, Pennsylvania.

What type of therapies does Krystal Biotech focus on?

The company focuses on genetic medicines for diseases with high unmet needs.

Last updated: May 7, 2025